GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Cash Flow from Financing

Roche Holding AG (XSWX:ROG) Cash Flow from Financing

: CHF-4,239 Mil (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Roche Holding AG paid CHF511 Mil more to buy back shares than it received from issuing new shares. It received CHF5,252 Mil from issuing more debt. It paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received CHF0 Mil from paying cash dividends to shareholders. It spent CHF522 Mil on other financial activities. In all, Roche Holding AG earned CHF4,219 Mil on financial activities for the six months ended in Dec. 2023.


Roche Holding AG Cash Flow from Financing Historical Data

The historical data trend for Roche Holding AG's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,173.00 -9,666.00 -13,108.00 -16,275.00 -4,239.00

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,052.00 -13,315.00 -2,960.00 -8,293.00 4,054.00

Roche Holding AG Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Roche Holding AG's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Roche Holding AG's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-4,239 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (XSWX:ROG) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Roche Holding AG's issuance of stock for the six months ended in Dec. 2023 was CHF-511 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Roche Holding AG's repurchase of stock for the six months ended in Dec. 2023 was CHF0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Roche Holding AG's net issuance of debt for the six months ended in Dec. 2023 was CHF5,252 Mil. Roche Holding AG received CHF5,252 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Roche Holding AG's net issuance of preferred for the six months ended in Dec. 2023 was CHF0 Mil. Roche Holding AG paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Roche Holding AG's cash flow for dividends for the six months ended in Dec. 2023 was CHF0 Mil. Roche Holding AG received CHF0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Roche Holding AG's other financing for the six months ended in Dec. 2023 was CHF-522 Mil. Roche Holding AG spent CHF522 Mil on other financial activities.


Roche Holding AG Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (XSWX:ROG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.